An Approved Vendor for
Over 14 Years

>500 Studies Supported

>225 Scientists
Supported

AstraZeneca has dedicated support from Strategic Account Management focused on orchestrating true enterprise-wide partnerships. Our aim is to streamline communications, strengthen relationships, facilitate agreements, broaden support, and expedite solutions to advance AstraZeneca projects.

Over the years, Discovery has delivered creative solutions across AstraZeneca Oncology and Biopharma R&D groups. Examples of these tailored services include customized and optimized NGS processes, low and high input NGS, whole genome, exome, targeted sequencing, and molecular pathology.

Discovery is a Level 1 and Level 2 AstraZeneca service provider supporting both prospective and retrospective clinical trials. Working with scientists throughout TM and CGR, Discovery now offers a wide range of genomic services including comprehensive genomic profiling, advanced nucleic acid extraction, whole genome, exome, transcriptome, single cell, and targeted sequencing services.  

Discovery has an agreement to supply GMP-compliant leukopaks to AstraZeneca development teams through our AllCell’s business. AllCells has the world’s largest apheresis capacity supporting both RUO and GMP-compliant collections. AllCell’s project management teams are ready to fully support AstraZeneca’s leukopak needs. 

• Largest selection available spanning most solid tumor indications
• World-class scientific support for DTCs utilization
• Flow and genomic characterizations available for optimal sample selections

• Pathologist reviewed, fully consented FFPE blocks and matched sets

• 40x Digital H&E images of all blocks for easy review and selection 

• Wide range of expert tissue biomarker and genomic services available

• GMP and RUO Leukopaks
• 99% delivery rate
• Tens of thousands of highly characterized donors available
• World's largest apheresis capacity to deliver RUO and GMP-compliant products

Reliable and customizable proteomic services from mass spectrometry to multiplexed immunoassays enabling improved understanding of real-time human biology.

High-throughput RNA-Seq, WES, targeted and pan-caner sequencing workflows optimized in GCLP-compliant service laboratories for the most challenging sample types such as FFPE and core needle biopsies. 

Pathologist-driven, GCLP compliant procedures for developing and validating custom mIF assays in CAP-accredited and CLIA-certified service laboratories.